Gemcitabine vs. 5-FU After Resection of Pancreatic Cancer
After resection of pancreatic cancer, median survival was longer with gemcitabine-based chemotherapy than with 5-FU–based chemotherapy. We still don’t know whether radiation therapy is needed.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)